Children's medicine welcomes the policy dividend again, and the market space is becoming wider and wider

Recently, in order to further consolidate the national essential medicine system and establish and improve the selection and adjustment mechanism of the national essential medicine list, the National Essential Medicines List Management Measures (Revised Draft) organized by the Department of Pharmaceutical Affairs of the National Health Commission has begun to solicit public opinions
.
Among them, it is worth noting that the catalog mentioned in the new plan will be divided into a catalog of chemical drugs and biological products, a catalog of Chinese medicines, and a catalog of children’s medicines.
A catalog of children’s medicines was released
.
The industry believes that the introduction of a children's drug list for the first time in the adjustment of the basic drug catalog will bring significant benefits to the children's drug market
.
According to data, from 2016 to 2019, the compound growth rate of China's children's medicine market sales was more than 10%.
Despite the impact of the epidemic in 2020, there will still be a market size of close to 70 billion yuan
.
In this context, analysts predict that while the new children's drug catalog will be in line with international standards, it will also further catalyze the R&D and innovation of children's drugs by domestic pharmaceutical companies
.
In fact, there has been a shortage of medicines for children in our country for a long time.
Therefore, the country has formulated a series of policies in recent years, including strengthening the provision of medicines for children in hospitals, directing bidding and purchasing directly on the Internet, encouraging research and development, and prioritizing review, etc.
Manufacturers increase R&D and production of medicines for children
.
For example, on September 29 this year, the State Food and Drug Administration issued an announcement requesting the instructions of five anti-tumor drugs that have been on the market to add information on medications for children
.
In addition, at the end of September, the state also issued the "China Children's Development Program (2021-2030)" to encourage the development and production of children's drugs, and accelerate the approval of children's drug applications
.
He also proposed to "explore and formulate a national children's essential medicine list, and timely update the children's banned drugs list"
.
At present, data shows that under the influence of a series of policies, the development and review and approval of children's medicines in 2021 have shown a significant increase in momentum
.
According to incomplete statistics, more than 10 children's medicines have been approved for marketing since 2021
.
Among them, some drugs also provide better dosage forms, such as vigabatrin powder for the treatment of infantile spasms, and nitisinone capsules for the treatment of type 1 tyrosinemia, etc.

.
In addition, there are currently more than 40 new pediatric drugs in the country at the stage of clinical approval and above
.
From the above point of view, China's children's medicine market has ushered in new development opportunities
.
Under the policy-guided research and development of children's drugs and the liberalization of the "three-child policy", the industry predicts that the market size of children's drugs will continue to maintain an average annual growth rate of more than double digits for a long time to come
.
At the same time, with the successive approval of new drugs, it will also bring more choices for children's medication
.
Generally speaking, in the context of favorable policies and the increasing attention of parents to the safety of children's medications, the market for children's medicines in China is expected to continue to rise in the future
.
Affected by this, the development momentum of exclusive and newly added varieties will also be very rapid, which will be good for manufacturers
.
However, it should be noted that opportunities and challenges often coexist.
While the future children's drug market will usher in an explosion, industry thresholds and bottlenecks, as well as competition, will also become not to be underestimated
.
For R&D companies, in addition to accelerating innovation, they also need to continue to pay attention to issues such as product channel sinking, and adjust their strategic layout in a timely manner
.